Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables
Ron Epelbaum(University of Bern), Yoram Cohen(Hebrew University of Jerusalem), Eliezer Robinson, Yehudit Ben-Arie(Technion – Israel Institute of Technology), Yishai Ron(University of Haifa), David Faraggi(Carmel (Israel)), Menahem Ben‐Shahar(University of Haifa), Nissim Haim(Technion – Israel Institute of Technology)
Cited by 122
Related Papers
QSAR without borders
|Chemical Society Reviews|2020|846
Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
|Current Medicinal Chemistry|2009|480
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
|British Journal of Cancer|2014|444
<sup>18</sup>F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients
|Journal of Nuclear Medicine|2009|381
Curcumin and Gemcitabine in Patients With Advanced Pancreatic Cancer
|Nutrition and Cancer|2010|279